385D Wiseman Hall
410 W 12th Ave
Columbus, OH 43210
Phone: (614) 292-3984
Email: kaur.11@osu.edu
Current OSU Appointment
Associate Professor, Neurological Surgery
Abstracts and Short Entries
Kaur B, Brat DJ, Catharine CC, Van Meir EG. 2002. Brain Angiogenesis Inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression [Abstract]. Georgia Life Sciences Summit. Atlanta, GA (Unspecified)
Kaur B, Brat DJ. 2003. Role of Brain Angiogenesis Inhibitor 1 as an anti-angiogenic factor for gliomas [Abstract]. American Association for Cancer Research (AACR) 94th Annual Meeting. Washington, DC (Unspecified)
Kaur B, Brat DJ, Devi NS, Van Meir EG. 2003. Brain Specific Receptor BAI1 can be cleaved to release a secreted extra cellular fragment which inhibits glioma growth and angiogenesis [Abstract]. 8th Annual Meeting, Society of Neuro-Oncology. Keystone, CO (Unspecified)
Kaur B, Sandberg EG, Brat DJ, and Van Meir EG. 2005. Vasculostatin is an extracellular proteolytic fragment of Brain Angiogenesis Inhibitor 1 that functions as a potent inhibitor of glioma growth and angiogenesis [Abstract]. EANO. Edinburgh (Unspecified)
Kurozumi K, Cutter J, Hardcastle J, Carson W, Chiocca EA, Kaur B. 2006. Anti-angiogenic treatment enhances anti-tumor effects of an oncolytic virus in an experimental rat glioma model [Abstract]. 8th Annual OSUCCC Scientific Meeting. Columbus, OH (Unspecified)
Jayson J Hardcastle, Kazuhiko Kurozumi, Martin P Sayers, Yoshinaga Saeki, E Antonio Chiocca, Balveen Kaur. 2007. RAMBO (Rapid Anti-angiogenesis mediated by Oncolytic virus) designed to destroy Tumors one pfu at a time [Abstract]. 6th Annual OSUMC Graduate & Post Graduate Research Day. Columbus, OH (Unspecified)
Kazuhiko Kurozumi, Jayson Hardcastle, Ming Yang, Gregory Christoforidis, William Carson, E. Antonio Chiocca, Balveen Kaur. 2007. Energizing VOLT (ViralOncolytic Therapy) [Abstract]. NeuroTumor Club Meeting. Los Angeles, CA (Unspecified)
Kazuhiko Kurozumi, Jayson Hardcastle, Ming Yang, Gregory Christoforidis, William Carson, E. Antonio Chiocca, Balveen Kaur. 2007. Modulation of Tumor Microenvironment to Enhance Oncolytic Virus Therapy [Abstract]. American Association for cancer research (AACR) annual Meeting (Formally Accepted)
Kazuhiko Kurozumi, Jayson Hardcastle, Ming Yang, Gregory Christoforidis, William Carson, E. Antonio Chiocca, Balveen Kaur. 2007. Synergy of Antiangiogenic treatment with Oncolytic virus therapy for brain tumors [Abstract] (Unspecified)
Jayson Hardcastle, Kazuhiko Kurozumi, Martin P. Sayers, Yoshinaga Saeki, E. Antonio Chiocca, and Balveen Kaur. 2008. A Novel Oncolytic Virus Designed To Modulate OV Induced Changes in Tumor Microenvironment [Abstract]. ASGCT 11th Annual Meeting. Boston, MA (Formally Accepted)
Kazuhiko Kurozumi, Alvarez-Breckenridge Christopher, Dmitrieva Nina, Jayson Hardcastle, E. A. Chiocca, Balveen Kaur. 2008. Oncolytic Virus Therapy of Glioma Sensitizes Glioma Cells to Cilengitide Treatment [Abstract]. ASGCT 11th Annual Meeting. Boston, MA (Formally Accepted)
Kazuhiko Kurozumi, Alvarez-Breckinridge, Kustikovich J, E. Antonio Chiocca, Balveen Kaur. 2008. Oncolytic HSV Therapy sensitizes glioma cells to integrin antagonists in vitro and in vivo [Abstract]. American Association for cancer research (AACR) annual Meeting (Formally Accepted)
Jayson Hardcastle, Kazuhiko Kurozumi, Nina Dmitrieva, Martin P Sayers, Sarwat Ahmad, Peter Waterman, Ralph Weissleder, E A Chiocca, Balveen Kaur. 2009. Vasculostatin expression mediated by oncolytic HSV-1 inhibits tumor angiogenesis and growth [Abstract]. American Society of Gene and Cell Therapy. San Diego, CA (Formally Accepted)
Kaur B. 2010. Impact of Tumor microenvironment on Oncolytic viral therapy [Abstract]. 13th Annual Meeting of the Translational Research Cancer centers Consortium Immune Suppression and the Tumor microenvironment (Unspecified)
Kaur B. 2011. The role of Tumor microenvironment on efficacy of Oncolytic viral therapy [Abstract]. 14th Annual Meeting of the Translational Research Cancer centers Consortium Immune Suppression and the Tumor microenvironment (Unspecified)
Chapters In Books
Barth R, Kaur B. 2009. Immunocompetent intracranial Rat glioma models for preclinical therapeutic evaluations of novel therapies. In CNC Cancer. Edited by Erwin Van Meir. Secacucus, NJ: Springer. (Formally Accepted)
Kaur B, Lesinsky G, Choudhary A,. Concept to Clinics, Development of Novel Therapeutics. In Development of Therapeutic agents. Edited by Shayne C Gad. Hoboken, NJ, USA: John Wiley and Sons. (In press)
Price R, Kaur B, Chiocca EA. 2011. Herpes Simplex Virus 1 for Cancer Therapy. In Gene Based Therapies for Cancer. Edited by Jack A Roth. Secacucus, NJ: Springer.
Compositions
OSUCCC - James' 2009-10 annual report. 2010. Research Highlights in New Tumor-Attacking Virus Strikes With One-Two Punch.
Degrees
| 1989 | B.S.(Honors), University of Delhi, Physics |
| 1991 | M.S., Banaras Hindu University, Biotechnology |
| 1999 | Ph.D., Emory University, Biochemistry and Molecular Biology |
Editor Reviewed Journal Articles
Kaur B, Chiocca EA. 2006. Oncolytic viruses: extreme treatment for an extreme disease. Future Microbiology. Vol. 1. (December 1): 351-353. http://www.ncbi.nlm.nih.gov/pubmed/17661625?ordinalpos=3&itool= EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum.
Kaur B, Chiocca EA. 2007. Personalizing oncolytic virotherapy?. Molecular Therapy. Vol. 15, no. 1. (January): 6-7. http://www.ncbi.nlm.nih.gov/pubmed/17164767?ordinalpos=5&itool=EntrezSystem2. PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum.
Editorial Activities
Ad Hoc Ad Hoc Reviewer
| 2007 | Neuro-Oncology. (Article) |
| 2007 | Brain, Behavior, and Immunity. (Article) |
Ad Hoc Reviewer
| 2010 | Human Gene Therapy. (Article) |
| 2008 | Cellular and Molecular Life Sciences. (Article) |
| 2008 | Plos One. (Article) (March 13, 2008). |
| 2008 | Oncogene. (Article) |
| 2007 | Journal of Neurovirology. (Article) |
| 2007 | Cellular Molecular Life Sciences. (Article) |
| 2007 | Molecular Therapy. (Article) |
| 2006 | Brain research. (Article) (March 13, 2008). |
| 2006 - present | blood. (Article) |
| 2006 | Cancer Chemotherapy and Pharmacology. (Article) |
| 2006 | Cancer gene Therapy. (Article) |
| 2006 | Future Oncology. (Article) |
| 2005 | Journal of Neuro-Oncology. (Article) (March 13, 2008). |
Honors
| 1989 - 1991 | Fellow, Fellowship. The Ohio State University, Columbus, OH, United States. |
| 1992 | Fellowship. The Ohio State University, Columbus, OH, United States. |
| 2002 | Distinguished Investigator Award. Georgia Life Sciences Summit. The Ohio State University, Columbus, OH, United States. ($1,000.00) Subject: Antiangiogenic treatment for brain tumors. |
| 2005 | Late breaking news Poster, EANO 2005, Edinburgh May 5-8. The Ohio State University, Columbus, OH, United States. |
| 2006 | Invited to Partcipate in Medical student summer fellowship Program. American Brain Tumor Association. The Ohio State University, Columbus, OH, United States. Subject: Brain Tumor Research |
| 2007 | Invited to Partcipate in Medical student summer fellowship Program. American Brain tumor Association. The Ohio State University, Columbus, OH, United States. Subject: Brain Tumor Research |
| 2007 | Invited Speaker, 2nd International Meeting Updates in Neuro-Oncology, Cortona Italy. Organizing committee 2nd International Meeting Updates in Neuro-Oncology, Cortona. Subject: Research |
| 2007 - 2009 | Fellow, Young Investigator Award,. Alex lemonade Stand Foundation.. The Ohio State University, Columbus, OH, United States. ($60,000.00) |
| 2008 | Honored at Faculty and Staff Recognition. Motor board and Sphinx. The Ohio State University, Columbus, OH, United States. |
| 2008 | Invited to Mentor a Medical student through the MSSF fellowship Program. American Brain Tumor Association.. The Ohio State University, Columbus, OH, United States. Subject: Brain Tumor Research |
| 2008 | Fellow, MENTORED RESEARCH AND CLINICAL SCIENTIST DEVELOPMENT AWARDS IN TRANSLATIONAL RESEARCH. NIH/NINDS. National Institutes of Health, Bethesda, MD, United States. ($525,633.00) Subject: Research |
| 2008 | Excellence in Teaching. The College of Medicine.. The Ohio State University College of Medicine, Columbus, OH, United States. Subject: Research |
| 2008 | Mortar Board and Sphinx. Mortar board and Sphinx. The Ohio State University, Columbus, OH, United States. |
| 2008 | Invited Lecturer, 13th Annual Gene Medicine Symposium, Stein Plaza, Los Angeles, CA. Stein Plaza, Los Angeles, CA. University of California, Los Angeles, CA, United States. Subject: research |
| 2008 | Invited Speaker Cincinnati children’s hospital, Cincinnati OH. Cincinnati children’s hospital, Cincinnati OH.. Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. Subject: Research |
| 2008 | Invited Speaker Medical College of Georgia Cancer center, Augusta GA. Medical College of Georgia Cancer center, Augusta GA.. Subject: Research |
| 2008 | Invited to lecture Pharmacology Seminar Series, Polaris OH. Pharmacology Seminar Series. The Ohio State University, Columbus, OH, United States. ($1,000.00) Subject: Research |
| 2009 | Invited to be External Thesis advisor, University of Ottawa, Canada. University of Ottawa, Canada. University of Ottawa, Ottawa, ON, Canada. Subject: Oncolytic viral therapy |
| 2009 | Consultant. Bexion pharmaceuticals. Bexion Pharmaceuticals, LLC., Covington, KY, United States. ($20,000.00) Subject: Research |
| 2009 | Abstract selected for oral presentation 12th Annual Meeting American Society for Gene Therapy,. American Society for Cell and Gene Therapy,. Subject: Research |
| 2009 | Invited to present at 5th International Oncolytic virus meeting, Banf, Canada. Organizin Committee, 5th International Meeting on replicating oncolytic virus therapeutics. Subject: Research |
| 2009 | Invited to be session chair, 7th Annual International Neuro-Oncology Updates. Organizing committee, 7th Annual International Neuro-Oncology Updates. The Ohio State University, Columbus, OH, United States. Subject: Research |
| 2010 | Invited to present my research at the 13th Translational Research Cancer centers Consortium. Translational Research Cancer centers Consortium. Subject: research |
| 2010 | Invited Education day speaker, 15th Annual Scientific meeting of the Society for Neuro-Oncology, Montreal, CA. Society for neuro-Oncology. Subject: Research |
| 2010 | Invited to Lecture students at Molecular medicine Seminar series at mayo Clinic. Mayo Clinic. Mayo Clinic, Rochester, MN, United States. ($250.00) Subject: research |
| 2011 | Invited to present at the 6th International conference on Oncolytic Viruses. Mayo Clinic. Mayo Clinic College of Medicine, Rochester, NY, United States. Subject: Research |
| 2011 | Abstract selected for Oral presentation, 14th Annual Meeting of American Society for Cell and Gene Therapy,. American Society of Gene & Cell Therapy. Subject: Research |
| 2011 | Invited to present my research at 14th Annual Meeting of the Translational Research Cancer centers Consortium, Silver Spring PA. Translational Research Cancer centers Consortium. Subject: research |
| 2011 | Finalist Alumni Award for Distinguished Teaching. The Ohio State University. The Ohio State University, Columbus, OH, United States. |
| 2011 | Invited by NIH to join DT study section as a permanent member. NationalInstitute of Health. National Institutes of Health (NIH), Bethesda, MD, United States. ($400.00) Subject: Grant review |
| 2011 | Invited to organize TRC3 Conference. TRC3 organizing committee. Subject: research |
| 2011 | Finalist for Alumni Award for Distinguished Teaching. The Ohio State University. The Ohio State University, Columbus, OH, United States. Subject: Teaching |
Inventions and Patents
Balveen Kaur, coinvento. (patent pending) US Patent application No. 12/697,891. Disc. Date: 2010.
Kaur Balveen, Avery Angela, Doetsch Paul, Co-Inventor. filed June 08, 1999 and issued February 28, 2007. Broad Specificity DNA Damage endonuclease. patent no. PCT/US1999/012910. Emory University.
Kaur Balveen, Angela Avery, Paul W Doetsch, Co-Inventor. filed January 31, 2002. (patent pending) Broad Specificity DNA damage endonuclease. patent no. U.S. Patent: 6,368,594.
Kaur Balveen, Avery Angela, Doetsch Paul, Co-Inventor. filed January 31, 2003 and issued February 25, 2003. Broad Specificity DNA damage endonuclease. patent no. Australian Patent: 760719.
Kaur Balveen, Avery Angela, Doetsch Paul, Co-Inventor. filed January 31, 2003 and issued February 25, 2003. Broad Specificity DNA damage endonuclease. patent no. Australian Patent: 760719.
Kaur Balveen, Yoshinaga Saeki, EA Chiocca, Inventor. filed October 17, 2007. (patent pending) Oncolytic virus. patent no. Provisional Patent Application: 60/980,664.
Kaur Balveen, Yoshinaga Saeki, EA Chiocca, Inventor. filed October 17, 2007. (patent pending) Oncolytic virus. patent no. Provisional Patent Application: 60/980,664.
Balveen Kaur, Coinventor. filed 2009. (patent pending) Oncolytic Virus. patent no. WO/2009/052426. Disc. Date: 2009.
Languages
Language/Dialect: Hindi, Reading Ability: Fluent, Writing Ability: Fluent, Speaking Ability: Fluent
English: (ability to read: Fluent, ability to write: Fluent, ability to speak: Fluent)
Language/Dialect: Sanskrit, Reading Ability: Basic, Writing Ability: Basic, Speaking Ability: Basic
Memberships
| 2003 - present | Member. American association for cancer research |
| 2004 - present | Member. Women in Cancer Research |
| 2006 - present | Member. American Society for Gene Therapy |
| 2006 - present | Member. Society for Neuro-Oncology |
| 2006 | Appointed Member. Molecular neurobiology and Neurological surfery. Search Committee |
| 2006 - present | Member. Ohio State University comprehensive Cancer center |
| 2006 - present | Member. Integrated Biomedical Science Graduate Program |
| 2007 - present | Member. Neuroscience Graduate Program |
| 2009 - present | Active Co-Chair. Brain Tumor Study group, Columbus, OH, USA. Brain Tumor Study group |
| 2009 - present | Acting Consultant. Brain Tumor Study group, Columbus, OH, USA. Bexion Pharmaceuticals |
| 2010 - present | Active Member. Member of American Association for Advancement of Science |
| 2010 - present | Active Organizer. Translational Research Cancer centers Consortium, Seven Springs, PA. 14th Annual Meeting of the Translational Research Cancer centers Consortium |
| 2011 - present | Active Leader. Ohio-Neuro-oncology consortium, Columbus, OH. Ohio-Neuro-oncology consortium |
| 2011 - present | Active Proposal Reviewer. NIH/CSR/Development therapeutics study section, Columbus, OH, USA. Study section Permanent member |
Outreach
Gene therapy for hematology and oncology
Project Dates: - present
Description: One hour Lecture on the preclinical and clinical research on gene therapy.
Women in Science
Project Dates: - present
Description: To educate young girls (grades 6-8) about career opportunities in Science.
dana fund
Project Dates: - present
Description: To help raize awareness for need to find novel cures for brain tumors.
Daniel J Zwayer Memorial Golf Tournament
Project Dates: - present
Description: Volunteered at a silent auction meant to raise money for brain tumor awareness and research.
13th annual UCLA gene Med Symposium
Project Dates: - present
Description: One hour lecture on the past and future development of oncolytic viral therapy.
Oncolytic viral therapy
Project Dates: - present
Description: Teching research faculty about oncolytic viral therapy.
Peer Reviewed Journal Articles
Kaur B, Avery AM and Doetsch PW,. 1998. Expression, Purification, and Characterization of Ultraviolet DNA Endonuclease from Schizosaccharomyces pombe. biochemistry. Vol. 37, no. 33. (August 18): 11599-11604. http://www.ncbi.nlm.nih.gov/pubmed/9708997?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum. (IF: 3.633)
Avery AM, Kaur B, Taylor JS, Mello JA, Essigmann JM and Doetsch PW. 1999. Substrate specificity of ultraviolet DNA Endonuclease (UVDE/Uve1p) from Schizosaccharomyces pombe. Nucleic acids research. Vol. 27, no. 11. (June 1): 2256-2264. (IF: 7.836)
Kaur B, Fraser JL, Freyer G, Davey S and Doetsch PW. 1999. A Uve1p mediated mismatch repair pathway in Schizosaccharomyces pombe. Molecular and cellular biology. Vol. 19, no. 7. (July): 4703-4710. (IF: 6.19)
Kaur B and Doetsch PW. 2000. Ultraviolet Damage Endonuclease (Uve1p): a Structure and Strand-Specific DNA Endonuclease. biochemistry. Vol. 39, no. 19. (May 16): 5788-5796. http://www.ncbi.nlm.nih.gov/pubmed/10801329?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum. (IF: 3.226)
Brat DJ, Castellano-Sanchez A, Kaur B, Van Meir E. 2002. Genetic and biologic progression in astrocytoma and their relation to angiogenic dysregulation. Advanced Anatomy and Pathology. no. 1. : 24-36.
Brat DJ, Castellano-Sanchez A, Kaur B, Van Meir E. 2002. Genetic and biologic progression in astrocytoma and their relation to angiogenic dysregulation. Adv. Anat. Pathol,. Vol. 9, no. 1. (January 9): 24-36. http://www.ncbi.nlm.nih.gov/pubmed/11756757?ordinalpos=10&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum. (IF: 2.420)
Majbeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG. 2002. Geldanamycin induces degradation of HIF-1a protein via the proteosome pathway in prostate cancer cells. cancer research. Vol. 62, no. 9. (May 1): 2478-2482. http://www.ncbi.nlm.nih.gov/pubmed/11980636?ordinalpos=9&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum. (IF: 7.656)
Fulci G, Nobuaki I, Daniela M, Gernert KM, Hainaut P, Kaur B, Van Meir EG. 2002. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of functions in a patient with a 283H p53 germ line mutation. cancer research. Vol. 62, no. 10. (May 15): 2897-2905. http://www.ncbi.nlm.nih.gov/pubmed/12019170?ordinalpos=8&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum. (IF: 7.656)
Brat DJ, Kaur B, Van Meir EG. 2003. Genetic Modulation of hypoxia induced gene expression and angiogenesis: Relevance to brain tumors. Frontiers in Bioscience,. Vol. 8. (January 1): d100-d116. http://www.ncbi.nlm.nih.gov/pubmed/12456339?ordinalpos=7&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum. (IF: 2.771)
Kaur B Brat DJ, Calkins CC, Van Meir E. 2003. Brain Angiogenesis Inhibitor 1 (BAI1) is differentially expressed in the normal brain and glioblastoma independently of p53 expression. american journal of pathology. Vol. 162, no. 1. (January 1): 19-27.-27. http://www.ncbi.nlm.nih.gov/pubmed/12507886?ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum. (IF: 5.917)
Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot MP, Cohen C, Hammond EH, Devi NS, Kaur B, Van Meir EG. 2004. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and likely represent an actively migrating cell population. cancer research. Vol. 64, no. 3. (February 1): 920-927. http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=14871821&ordinalpos=5&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum. (IF: 7.656)
Kaur B, Tan C, Brat DJ, Van Meir EG. 2004. Genetic and hypoxic regulation of angiogenesis in gliomas. Journal of Neurooncology. Vol. 70, no. 2. (November): 229-243. http://www.ncbi.nlm.nih.gov/pubmed/15674480?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum. (IF: 1.848)
Post DE, Devi NS, Li Z, Brat DJ, Kaur B,Nicholson A, Olson JJ, Zhang Z, Van Meir EG. 2004. Cancer Therapy with a replicating adenovirus targeting the hypoxic microenvironment of tumors. Clinical Cancer Research.. Vol. 10, no. 24. (December 15): 8603-8612. http://www.ncbi.nlm.nih.gov/pubmed/15623644?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum. (IF: 6.177)
Kaur B, Brat DJ, Devi NS, Van Meir EG. 2005. Vasculostatin, a natural BAI1 proteolytic fragment is an anti-angiogenic and anti-tumorigenic factor. Oncogene. Vol. 24. : 3632-3642.
Kaur B. Khwaja FK, Severson EA, Matheny S, Brat DJ, Van Meir EG. 2005. Hypoxia and the HIF pathway in glioma growth and angiogenesis. Neuro-Oncology. Vol. 2, no. 7. (April): 134-153.
Kaur B, Brat DJ, Devi NS, Van Meir EG. 2005. Vasculostatin a proteolytic fragment of Brain Angiogenesis Inhibitor 1 is an Antiangiogenic and antitumorigenic factor. Oncogene. Vol. 24, no. 22. (May 19): 3632-3642. http://www.ncbi.nlm.nih.gov/pubmed/15782143?ordinalpos=2&itool=EntrezSystem2.PEntrez. Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum. (IF: 6.582)
Kaur B, Chiocca EA. 2006. Extreme treatment for an extreme disease. Future Microbiology. Vol. 4, no. 1. : 351-353.
Cutter JL, Kurozumi K, Chiocca EA, Kaur B. 2006. Gene therapeutics: The future of brain tumor therapy. Expert Review of Anticancer Therapy 6(7):1053-64.. Vol. 6, no. 7. (July): 1053-1064. http://www.ncbi.nlm.nih.gov/pubmed/16831077?ordinalpos=8&itool=EntrezSystem2.PEntrez. Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum.
Fulci, G. Breymann, L. Gianni, D. Kurozomi, K. Rhee, S. S. Yu, J. 2006. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A.. Vol. 103, no. 34. (August 22): 12873-12878. http://www.ncbi.nlm.nih.gov/pubmed/16908838?ordinalpos=7&itool=EntrezSystem2. PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum. (IF: 9.643)
Kaur B, Chiocca EA. 2006. Future Microbiology. Oncolytic viruses: extreme treatment for an extreme disease.. Vol. 1. (December): 351-353. http://www.ncbi.nlm.nih.gov/pubmed/17661625?ordinalpos=3&itool= EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum.
Lamfers, M. L. Fulci, G. Gianni, D. Tang, Y. Kurozumi, K. Kaur, B. Moeniralm, S. 2006. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Molecular Therapy. Vol. 14, no. 6. (December): 779-788. http://www.ncbi.nlm.nih.gov/pubmed/16996314?ordinalpos=6&itool=EntrezSystem2.PEntrez. Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum. (IF: 7.15)
Kaur B, Chiocca EA. 2007. Personalizing oncolytic virotherapy?. Molecular Therapy. Vol. 15, no. 1. (January): 6-7. http://www.ncbi.nlm.nih.gov/pubmed/17164767?ordinalpos=5&itool=EntrezSystem2. PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum. (IF: 5.841)
Hardcastle J, Kurozumi K, Chiocca EA, Kaur B. 2007. Oncolytic Viruses driven by tumor specific promoters. Current Cancer Drug Targets.. Vol. 7, no. 2. (March): 181-189. http://www.ncbi.nlm.nih.gov/pubmed/17346110? ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum. (IF: 5.677)
Fulci G, Dmitrieva N, Gianne D, Fontana EJ, Pan X, Kaur B, Lawler S, Lee RJ, Marsh CB, Brat DJ, Van Roojen N, Rachamimov AS, Weissleder RW, Martuza RL, Chiocca EA. 2007. Depletion of macrophages or microglia increases the titers of injected oncolytic viruses. Cancer research. Vol. 67, no. 19. (October 1): 9398-406-9406. http://www.ncbi.nlm.nih.gov/pubmed/17909049?ordinalpos=2&itool=EntrezSystem2.PEntrez. Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum. (IF: 7.656)
Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G, Hochberg FH, Weissleder RW, Carson W, Chiocca EA, Kaur B. 2007. Modulation of Tumor microenvironment to enhance Oncolytic virus therapy. Journal of National Cancer Institute.. Vol. 99, no. 23. (December): 1768-1781. http://www.ncbi.nlm.nih.gov/sites/ entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=18042934&ordinalpos=1&itool=EntrezSystem2.PEntrez. Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum. (IF: 14.69)
Kurozumi K, Hardcastle J, Thakur T, Shroll J, Nowicki M, Otsuki A, Chiocca EA, Kaur B. 2008. ONCOLYTIC HSV-1 INFECTION OF TUMORS INDUCES ANGIOGENESIS ANDUPREGULATES CYR61. Molecular Therapy. no. In Press. http://www.ncbi.nlm.nih.gov/pubmed/18545226?ordinalpos=1&itool=EntrezSystem2.PEntrez. Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum. (IF: 7.15)
Alvarez-Breckenridge C, Kaur B and Chiocca EA. 2009. Pharmacologic and chemical adjuvants in tumor virotherapy. Chemical reviews. Vol. 109, no. 7. : 3125-3140. http://www.ncbi.nlm.nih.gov/pubmed/19462957?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ ResultsPanel.Pubmed_RVDocSum&ordinalpos=1. (IF: 23.52)
Kaur B, Cork SM, Sandberg E, Devi NS, Zhang Z, Klenotic PA, Febbraio M, Shim H, Mao H, Tucker-Burden C, Silverstein RL, Brat DJ, Olson JJ, and Van Meir EG. Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Research. (In press)
Kaur B, Cripe T, Chiocca EA. 2009. Buy one get one free:" armed viruses for the treatment of cancer cells and their microenvironment. Current Gene Therapy. Vol. 9, no. 5. : 341-355. http://www.ncbi.nlm.nih.gov/pubmed/19860649?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ ResultsPanel.Pubmed_RVDocSum&ordinalpos=1. (IF: 4.902)
Haseley A, Alvarez-Breckenridge C Chaudhury AR, Kaur B. 2009. Advances in Oncolytic virus Therapy for Glioma. Recent Patents on CNS Drug Discovery. Vol. 4, no. 1. (January): 1-13.
Barth RF, Kaur B. 2009. Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. Journal of Neuro-oncology. Vol. 3, no. 94. (September): 299-312.
Hardcastle J, Kurozumi K, Sayers P, Chiocca EA, Kaur B. 2010. Generation and testing of RAMBO (Rapid antiangiogenisis mediated by Oncolytic virus) for treatment of brain tumors. Molecular Therapy. Vol. 18, no. 2. : 285-294. http://www.ncbi.nlm.nih.gov/pubmed/19844198?itool=EntrezSystem2. PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=2. (IF: 5.97)
Nakashima H, Kaur B, Chiocca EA. 2010. Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine & growth factor reviews. (IF: 8.239)
Wojton J, Kaur B. 2010. Impact of tumor microenvironment on oncolytic viral therapy. Cytokine & growth factor reviews. (IF: 8.239)
Hardcastle J, Kurozumi K, Dmitrieva N, Sayers MP, Ahmad S, Waterman P, Weissleder R, Chiocca EA, Kaur B. 2010. Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Molecular Therapy. Vol. 2, no. 18. (February): 285-294. (IF: 7.15)
Klenotic PA, Palomo J, Kaur BVan Meir EG, Vogelbaum MA, Febbraio M and Silverstein RL. 2010. Histidine-rich Glycoprotein Modulates the Anti-angiogenic Effects of Vasculostatin. American Journal of Pathology. Vol. 176, no. 4. (April): 2039-2050. http://www.ncbi.nlm.nih.gov/pubmed/20167858. (IF: 5.224)
Chiocca EA, Aguilar LK, Bell S, Kaur B, Hardcastle J, Cavaliere R, McGregor J, Lo S, RayChaudhuri A, Chakarvarti AG, Herbert JN, Harris KS, Grossman RG, Trask TW, Baskin DS, Monterroso CM, Manzanera AG, Aguilar-Cordova E, New PZ. 2011. Phase Ib Study of Gene Mediated Cytotoxic Immunotherapy Adjuvant to Up-Front Surgery and Intensive Timing Radiation for Malignant Glioma. Journal of Clinical Oncology. (IF: 18.97) (Formally Accepted)
Kaur B, Chiocca EA, Cripe TP. 2011. Oncolytic HSV-1 Virotherapy; Clinical Experience and Opportunities for Progress. Current Pharmaceutical Biotechnology, special issue "Virology". (IF: 3.455)
Williams SP, Nowicki MO, Liu F, Press R, Godlewski J, Abdel-Rasoul M, Kaur B, Fernandez SA, Chiocca EA, Lawler SE. 2011. Indirubins Decrease Glioma Invasion by Blocking Migratory3 Phenotypes in Both the Tumor and Stromal Endothelial4 Cell Compartments. Cancer Research. no. In Press. (IF: 8.234)
Yoo JY, Haseley A, Bratasz A, Chiocca EA, Zhanf JY, Cain D, Powell K, Kaur, B. 2011. Antitumor Efficacy of 34.5ENVE: a transcriptionally retargeted and Vstat120 expressing oncolytic virus. Molecular therapy. (IF: 7.15) (Formally Accepted)
Dmitrieva N, Yu L, Viapiano M, Chiocca EA, Cripe T, Glorioso J, Kaur B. 2011. Choindroitinase ABC I enhances intra-tumor distribution and anti-tumor efficacy of oncolytic virus. Clinical Cancer research. Vol. 6, no. 17. (March 15): 1362-1372. (IF: 7.34)
Cork SM, Kaur B, Devi NS, Cooper L, Saltz JH, Sandberg EM, Kaluz S, Van Meir EG. 2012. A furin/MMP-14 proteolytic cascade releases a novel 40 kDa vasculostatin from tumorsuppressor BAI1. Oncogene. no. In Press. (IF: 7.414) (Formally Accepted)
Positions
| 1994 - 1999 | Graduate research associate, Emory University, Graduate school of arts and sciences, Department of Biochemistry. Atlanta, GA, United States. |
| 1999 - 2004 | Post doctoral fellow, Emory University School of Medicine, neurological surgery. Atlanta, GA, United States. |
| 2003 - 2004 | Research Associate, Emory University, Medicine, Neurological Surgery. Atlanta, GA, United States. |
| 2004 - 2005 | Senior research associate, Emory University School of Medicine, medicine, Neurological surgery. Atlanta, GA, United States. |
| 2005 - 2005 | Visiting Asst Professor-Be , The Ohio State University, Neurological Surgery . Columbus, OH, United States. |
| 2005 - 2009 | Assistant Professor, The Ohio State University, Medicine, Neurological Surgery. Columbus, OH, United States. |
| 2007 - present | Faculty, Neuroscience Graduate studies Program, The Ohio State University College of Medicine, Neurological Surgery. Columbus, OH, United States. |
| 2008 - present | Director Research relations, The Ohio State University, Medicine, Neurological surgery. Columbus, OH, United States. |
| 2009 - present | Associate Professor, The Ohio State University, Medicine, Neurological Surgery. Columbus, OH, United States. |
| 2009 - present | Chief Dardinger Laboratories, The Ohio State University, Medicine, Neurological Sugery. Columbus, OH, United States. |
Presentations
Invited Presentations
Local
Balveen Kaur, Presenter. 2007. Personalizing Oncolytic Viral Therapy. Presented at The Department of Laboratory Medicine Retreat. Ohio Historical Society. Columbus, OH.
Jayson J Hardcastle. 2007. RAMBO (Rapid Anti-angiogenesis mediated by Oncolytic virus) designed to destroy Tumors one pfu at a time. Presented at 6th Annual OSUMC Graduate & Post Graduate Research Day. The Ohio State University.
Kazuhiko Kurozumi. 2007. Synergy of Antiangiogenic treatment with Oncolytic virus therapy for brain tumors.
Balveen Kaur, Lecturer. 2007. Energizing VOLT: Viral Oncolytic therapy. Presented at Grand Rounds: Neurological surgery. The Ohio state University. Columbus, OH. (August)
Balveen Kaur, Chair. 2008. Tumor Microenvironment and Oncolytic virus therapy. to Cincinnati children's hospital,. Cincinnati, OH.
Balveen Kaur, Presenter. 2008. Gene Therapy in Hematology and Oncology. Presented at Pharmacology Seminar Series. Polaris, OH. (January)
Balveen Kaur, Lecturer. 2008. Journey Of Oncolytic viruses; Hood to hospital. Presented at Pediatric Oncology Program retreat., to Cincinnati children's hospital,. Wilmington, OH. (September)
Brain tumor study group, Lecturer. 2010. Impact of tumor microenvironment on OV therapy. Presented at Brain tumor study group. columbus, OH.
Balveen Kaur, Panelist. 2011. "How to Get There from Here". Presented at Ohio State's Center for Clinical and Translational Science, 2011 Research Celebration. Columbus, Ohio. (April 6)
Balveen Kaur, Lecturer. 2011. Oncolytic Viruses and cancer therapy. Presented at Viral Oncology Program Retreat, to ViralOncology Program members. Columbus, OH. (June 16)
State
Balveen Kaur, Lecturer. 2011. CNS cancer therapeutic research. Presented at Ohio Neuro-Onc research day. columbus, OH.
Regional
Balveen Kaur, Lecturer. 2008. Gene Therapy in Hematology and oncology. Presented at Pharmacology Seminar Series. Columbus, OH. (January)
Balveen Kaur, Lecturer. 2008. Tumor Microenvironment and Oncolytic virus therapy. Presented at Cincinnati children's hospital. Cincinnati, OH. (September)
National
Jayson Hardcastle. 2008. A Novel Oncolytic Virus Designed To Modulate OV Induced Changes in Tumor Microenvironment. Presented at ASGCT 11th Annual Meeting. Boston, MA.
Kazuhiko Kurozumi. 2008. Oncolytic Virus Therapy of Glioma Sensitizes Glioma Cells to Cilengitide Treatment. Presented at ASGCT 11th Annual Meeting. Boston, MA.
Balveen Kaur, Presenter. 2008. The Tumor and its Microenvirnment and Oncolytic Viruses: Friends and Foes in Battle. Presented at 13th Annual Gene Medicine Symposium. Stein Plaza. Los Angeles, CA. (May)
Balveen Kaur, Lecturer. 2008. The Tumor and its Microenvironment and Oncolytic Viruses: Friends and Foes in Battle. Presented at 13th Annual Gene Medicine Symposium. Stein Plaza. Los Angeles, CA. (May)
Balveen Kaur, Lecturer. 2008. Recharging VOLT: Viral Oncolytic therapy, Medical College of Georgia Cancer center, Augusta GA. June 2008. Presented at Medical College of Georgia Cancer center, to Medical College of Georgia Cancer center,. Medical College of Georgia Cancer center,. Augusta, GA. June 2008., USA. (June)
Balveen Kaur, Lecturer. 2009. Oncolytic Viral therapy for brain tumors: Bench to bed and back to bench. Presented at Simmons Cancer Institute at Southern Illinois University. springfield, IL.
Balveen Kaur, Presenter. 2010. Impact of Tumor Microenvironment on Oncolytic Viral Therapy. Presented at 13th Annual Meeting of the Translational Research Cancer Centers Consortium. Columbus, OH. (March)
Balveen Kaur, Lecturer. 2010. Oncolysis and the Tumor Microenvironment. Presented at Molecular Medicine Seminar series. Mayo Clinic. Rochester, MN. (June)
Balveen Kaur, Presenter. 2010. Oncolysis and Tumor Microenvirnment. Presented at Molecular Medicine Seminar Series. Mayo Clinic. Rochester, MN. (June)
Balveen Kaur, Lecturer. 2011. Impact of Tumor microenvironment on Oncolytic viral therapy. Presented at 14th Annual Meeting of the Translational Research Cancer centers Consortium. Silver Springs, PA. (February)
Balveen Kaur, Presenter. 2011. The role of tumor microenvironment on efficacy of oncolytic viruses. Presented at 14th Annual Meeting of the Translational Research Cancer Centers Consortium. Seven Springs, PA. (February)
International
Balveen Kaur, Presenter. 2007. Modulation of Tumor Microenvironment to Enhance Oncolytic Virus Therapy. Presented at 2nd International Meeting Updates in Neuro-Oncology. Cortona, Italy. (June)
Balveen Kaur, Lecturer. 2008. The Tumor and its Microenvironment and Oncolytic Viruses: Friends and Foes in Battle. Presented at 13th Annual Gene Medicine Symposium,. Stein Plaza,. Los Angeles,, CA, USA. (May)
Balveen Kaur, Lecturer. 2009. Impact of tumor microenvironment on OV therapy. Presented at 5th International Oncolytic virus meeting,. Banf, Canada, CA. (March)
Balveen Kaur, Presenter. 2009. Vasculostatin Expression Mediated by Oncolytic HSV-1 Inhibits Tumor Angiogenesis and Growth. Presented at American Society of Gene & Cell Therapy 12th Annual Meeting. San Diego, CA. (June)
Balveen Kaur, Lecturer. 2009. Vasculostatin expression mediated by oncolytic HSV-1 inhibits tumor angiogenesis and growth. Presented at ASGCT 12th Annual Meeting. San Diego, CA. (June)
Balveen kaur, Presenter. 2010. Novel Anti-Angiogenic Agents/Therapeutics Showing Efficacy in Preclinical Brain Tumor Models. Presented at 15th Annual Scientific Meeting of the Society for Neuro-Oncology. Montreal, Canada. (November)
Balveen Kaur, Lecturer. 2011. Vstat120 modulates innate pro-inflammatory response to OV therapy. Presented at American Society for Cell and gene therapy. Seattle, WA, USA.
Balveen Kaur, Lecturer. 2011. Extracellular Barriers to Oncolysis. Presented at 6th International conference on Oncolytic Viruses. Las Vegas, NV. (March)
Other Presentations
Local
Balveen Kaur, Presenter. 2001. Absence of expression of Brain specific angiogenesis inhibitor 1 in glioblastoma multiforme. Presented at Winship Cancer Institute, Director's Seminar. Emory University, Atlanta, GA.
Balveen Kaur, Presenter. 2002. Ultra violet DNA endonuclease, a broad specificity DNA repair endonuclease. Presented at Invited Seminar Series. Clontech, Palo Alto, CA, USA.
Balveen Kaur. 2003. Brain Specific Receptor BAI1 can be cleaved to release a secreted extra cellular fragmentwhich inhibits glioma growth and angiogenesis. Presented at 8th Annual Society for Neuro-Oncologymeeting. Keystone Colorado.
Balveen Kaur, Presenter. 2003. Characterization of Brain specific angiogenesis inhibitor 1. Presented at Molecular mechanisms inBrain tumors. Houston, Texas.
Balveen Kaur, Presenter. 2003. Proteolytic fragment of BAI1 is a novel anti-angiogenic and anti-tumorigenic factor. Presented at Invited Speaker Seminar. Trevigen Inc. Gaithersburg, MD.
Balveen Kaur, Presenter. 2003. sBAI1, a Proteolytic fragment of BAI1 is a novel anti-angiogenic and anti- tumorigenicfactor. Presented at Winship Cancer Institute, Director's Seminar Series. Emory University, Atlanta, GA.
Balveen Kaur, Presenter. 2003. Vasculostatin, a novel anti-angiogenic and anti-tumorigenic factor in the brain. Presented at ABC2 sitevisit. Winship Cancer Institute, Emory Univesity, Atlanta, GA. USA.
Balveen Kaur. 2004. ECD, a proteolytic fragment of BAI1 is a novel anti-angiogenic and anti-tumorigenic factor. Presented at Neurosurgery, Grand rounds. Emory University, School of Medicine, Atlanta, GA.
Balveen Kaur, Editor. 2004. Significance of Brain angiogenesis inhibitor 1 (BAI1), in gliomagenesis. Presented at Invited Speaker, MassachusettsGeneral Hospital, Neurosurgery Department. Charlestown, MA. USA. [Editor Reviewed]
Balveen Kaur, Editor. 2006. Enhancement of OV mediated Oncolysis by vessel normalization. Presented at Center For Molecularneurobiology Seminar Series. The Ohio State University, Columbus, OH. USA. [Editor Reviewed]
Balveen Kaur, Editor. 2006. Host responses to HSV-1 derived OV. Presented at Viral Oncogenesis Program Retreat, OSUCCC. WorthingtonInn, Worthington OH. [Editor Reviewed]
Balveen Kaur. 2006. Host Responses to Oncolytic Viruses. Presented at Grand Rounds, Viral Oncogenesis Program,OSUCCC. The Ohio State University, Columbus, OH.
Balveen Kaur, Presenter. 2006. Oncolytic virus Treatment of brain tumors: What went wrong? Presented at Gene Therapy forBrain tumors meeting. Massachusetts General hospital, Charlestown MA.
Balveen Kaur. 2006. Oncolytic Viruses: The good the bad and the ugly:. Presented at Brain Tumor Seminar Group series. The Ohio State University, Columbus, OH.
Balveen Kaur, Presenter. 2007. Cilengitide in combination with oncolytic viruses. Presented at NCI Investigator Meeting Cilengitide, ASCO. Chicago, IL. USA.
Balveen Kaur, Presenter. 2007. Energizing VOLT: Viral Oncolytic therapy,. Presented at Grand Rounds: Neurological surgery, The Ohio State University. The Ohiostate University, Columbus, OH.
Balveen Kaur, Presenter. 2007. Modulation of tumor microenvironment to enhance Oncolytic virus Therapy,. Presented at Neuro TumorClub Meeting Hosted by Society for Neuro-Oncolgy. Los Angeles, CA. USA.
Balveen Kaur, Presenter. 2007. Modulation of Tumor microenvironment to enhance Oncolytic virus therapy. Presented at 2ndInternational Meeting Updates in Neuro-Oncology. Cortona (AR) Italy,.
Balveen Kaur, Editor. 2007. Personalizing Oncolytic viral Therapy. Presented at The Department Of Laboratory Medicine Retreat,. Ohio Historical Society, Columbus, OH. USA. [Editor Reviewed]
Balveen Kaur, Presenter. 2008. Gene therapy for hematology and Oncology. Presented at Seminar series in Hematology and Oncology. Polaris, OH. USA.
Professional Activities
Community Service
| 2008 | Participation in student recruitment for incoming IBGP students. Fundraising. |
Conference Participation
| 2009 | Viral Oncology Program seminar series. Panelist. Viral Oncogenesis Program, OSUCCC. OSU. Columbus, OH. |
| 2010 | VOP seminar series. Panelist. Viral Oncogenesis Program, OSUCCC. OSU. Columbus, OH. |
| 2010 - present | Co-Chair Brain Tumor Study group. Panelist. Brain tumor study group. OSU. Columbus, OH. |
| 2011 | Meeting Co-organizer, Translational Research Cancer Centers Consortium. Panelist. Meeting Co-organizer, Translational Research Cancer Centers Consortium. |
| 2011 | Co-Chair, Brain tumor study group. Panelist. Brain tumor study group. |
| 2011 | Viral oncology program retreat. Panelist. Viral Oncogenesis Program, OSUCCC. The Longaberger Alumni House. Columbus, OH. |
| 02/24/2011 - 02/26/2011 | Meeting organizer. Panelist. Meeting Co-organizer, Translational Research Cancer Centers Consortium. Seven Springs Resort. Seven Springs, PA. |
Consultation
| 03/10/2007 - present | Consultant for SapC-DOPS nanovesicle glioma therapy studies. Industry. Cincinnati Children's Hospital Medical Center. Cincinnati,, OH, 45229. Key achievements: Shared expertise on glioma models in mice, permitting evaluation of Sap-C DOPS for glioma therapy. |
| 2008 | Consultant for SapC-DOPS nanovesicle glioma therapy studies. Industry. Bexion Pharmaceuticals. |
| 2009 | Consultant for SapC-DOPS nanovesicle glioma therapy studies. Industry. Bexion Pharmaceuticals. |
| 2010 | Consultant for SapC-DOPS nanovesicle glioma therapy studies. Industry. Bexion Pharmaceuticals. |
| 2011 | Consultant for SapC-DOPS nanovesicle glioma therapy studies. Industry. Bexion. |
Education
| 2010 | OSUMC research day. Evaluator. OSUMC Annual resrearch day. OSU. Columbus, OH, USA. |
| 2011 | osumc research day. Evaluator. OSUMC annual research day. OSU. Columbus, OH. |
Research
| 05/16/2008 | NIH/CSR Special Emphasis Panel/Scientific Review Group 5/16/2008 ZRG1 ONC-W (91). Grant Reviewer. NIH/CSR. |
| 09/18/2008 - 09/19/2008 | NIH/CSR Developmental Therapeutics Study Section 9/18/08-9/19/08. Grant Reviewer. NIH/CSR. |
| 10/30/2008 - 10/31/2008 | NIH/CSR Scientific review group ZRG1 ONC-U (92) study section. Grant Reviewer. National Institute of Health. |
| 2009 | Landacre Honor Society, Roessler Scholarship for medical students. Proposal Reviewer. OSUMC. |
| 2009 | NIH/CSR Scientific review group ZRG1 BDCN-T (03) M study section. Grant Reviewer. NIH/CSR. Washington DC, USA. |
| 06/11/2009 | NIH/CSR Developmental Therapeutics Study Section. Grant Reviewer. NIH/CSR. Washington DC, USA. |
| 11/06/2009 | The Ohio State University Center for Clinical & Translational Science (CCTS) Pilot and Collaborative Translational and Clinical Studies Program. Proposal Reviewer. The Ohio State University Center for Clinical & Translational Science (CCTS). Columbus, OH, USA. |
| 2010 - present | Well being for Women. Grant Reviewer. RCOG research Grants. columbus, OH, USA. |
| 2010 | Landacre Honor Society, Roessler Scholarship for medical students. Proposal Reviewer. OSUMC. columbus, OH, USA. |
| 01/28/2010 | NIH/CSR Scientific review group Developmental Therapeutics Study Section. Grant Reviewer. NIH/CSR. San Diego, CA, USA. |
| 03/23/2010 | NIH/CSR Scientific review group Special Emphasis Panel ZRG1 OTC-K (05). Grant Reviewer. NIH/CSR. Columbus, OH, USA. |
| 05/24/2010 | NIH/CSR Scientific review group Tumor Progression and Metastasis Study Section. Grant Reviewer. NIH/CSR. washington dc, DC, USA. |
| 08/05/2010 | NCI Scientific review group NCI IRM STRAP Study Section. Grant Reviewer. NCI. |
| 09/22/2010 - 09/24/2010 | NIH/CSR Scientific review group Developmental Therapeutics Study Section. Grant Reviewer. NIH/CSR. columbus, OH. |
| 2011 | Landacre Honor Society, Roessler Scholarship for medical students. Proposal Reviewer. Landacre Honor Society, Roessler Scholarship for medical students. columbus, OH. |
| 2011 | Discovery, Imaging and Therapeutics P01 review. Grant Reviewer. NIH/NCI. |
| 06/12/2011 - 06/14/2011 | NIH/CSR Scientific review group Developmental Therapeutics Study Section. Grant Reviewer. NIH/CSR. San Francisco, CA. |
Service to Student Affairs
| 2008 | Participation in student recruitment for incoming NGSP students. Student Orientation. Participation in student recruitment for incoming NGSP students. |
| 2008 | Participation in student recruitment for incoming IBGP students. Student Orientation. Participation in student recruitment for incoming IBGP students. |
| 2008 | Participation in student recruitment for incoming BMS honors students. Student Orientation. Participation in student recruitment for incoming BMS honors students. |
| 2009 | Participation in student recruitment for incoming IBGP students. Student Orientation. Participation in student recruitment for incoming IBGP students. |
| 2009 | Participation in student recruitment for incoming NGSP students. Student Orientation. Participation in student recruitment for incoming NGSP students. |
| 2009 | Participation in student recruitment for incoming BMS honors students. Student Orientation. Participation in student recruitment for incoming NGSP students. |
| 2010 | Participation in student recruitment for incoming NGSP students. Student Orientation. Participation in student recruitment for incoming NGSP students. |
| 2010 | Participation in student recruitment for incoming IBGP students. Student Orientation. Participation in student recruitment for incoming IBGP students. |
| 2010 | Participation in student recruitment for incoming BMS honors students. Student Orientation. Participation in student recruitment for incoming BMS honors students. |
Reviews
2007. Personalizing Oncolytic Virotherapy. Review of . Molecular therapy: 6-7. ()
kaur B, Chiocca EA. 2007. Extreme treatment for an extreme disease. Review of . Future Microbiology. 1(4):351-353.: 351. ()
Undergrad., Grad. and Prof. Courses Taught
Winter 2006. The Ohio State University, IBGP 999, Disertation research.
Spring 2006. The Ohio State University, IBGP 999, Disertation research.
Summer 2006. The Ohio State University, Biology 693 693.
Summer 2006. The Ohio State University, IBGP 999, Disertation research
Summer 2006. The Ohio State University College of Medicine, Summer medical Student research
Autumn 2006. The Ohio State University College of Medicine, Biology 693 Biology 693.
Autumn 2006. The Ohio State University, IBGP 999 Disertation research IBGP 999,.
2006. The Ohio State University, IBGP 999, Disertation research
Winter 2007. The Ohio State University College of Medicine, BMS 720.01 BMS Honors research experience
Winter 2007. The Ohio State University College of Medicine, Biology H783.
Winter 2007. The Ohio State University, Dissertation Research IBGP 702.04.
Winter 2007. The Ohio State University, IBGP. IBGP 702.04 Module 8, Cancer biology IBGP 702.04. 10 credit hours
Winter 2007. The Ohio State University, IBGP797.
Winter 2007. The Ohio State University, Pathology 850
Winter 2007. The Ohio State University, Pathology 850
Winter 2007. The Ohio State University, Pathology 850
Winter 2007. The Ohio State University, IBGP797
Winter 2007. The Ohio State University, Pathology 850
Spring 2007. The Ohio State University, IBGP797
Summer 2007. The Ohio State University, IBGP797
Summer 2007. The Ohio State University College of Medicine, Summer Medical Student Research
Summer 2007. The Ohio State University College of Medicine, Summer Medical Student research
Autumn 2007. The Ohio State University, IBGP797
Autumn 2007. The Ohio State University, NSGP. Neuroscience Program Seminar Series NGSP797.
Winter 2008. The Ohio State University, Dissertation Research IBGP 999. 15 credit hours
Winter 2008. The Ohio State University, BMS Honors Research Experience BMS 720.1. 5 credit hours
Winter 2008. The Ohio State University, Dissertation Research NGSP 693. 2 credit hours
Spring 2008. The Ohio State University, Dissertation Research IBGP 999. 15 credit hours
Spring 2008. The Ohio State University, BMS Honors Research Experience BMS 720.1. 5 credit hours
Summer 2008. The Ohio State University, Dissertation Research IBGP 999. 15 credit hours
Summer 2008. The Ohio State University, BMS Honors Research Experience BMS 720.1. 5 credit hours
Summer 2008. The Ohio State University, Dissertation Research NGSP 999. 5 credit hours
Autumn 2008. The Ohio State University College of Medicine, BMS Honors Research Experience
Autumn 2008. The Ohio State University, Seminar Topics in Neuroscience NGSP 797. 1 credit hours
Autumn 2008. The Ohio State University, Dissertation Research NGSP 999. 5 credit hours
Winter 2009. The Ohio State University College of Medicine, IBGP Dissertation Research IBGP 999. 15 credit hours
Winter 2009. The Ohio State University College of Medicine, Integrated Biomedical Science. NEURSGY 999 Dissertation Res NEURSGY 999. 18 credit hours
Spring 2009. The Ohio State University College of Medicine, Integrated Biomedical Science. IBGP 999 Dissertation Res IBGP 999. 18 credit hours
Spring 2009. The Ohio State University College of Medicine, Integrated Biomedical Science. NEURSGY 999 Dissertation Res NEURSGY 999. 18 credit hours
Summer 2009. The Ohio State University College of Medicine, IBGP 999 Disserttation Research IBGP 999. 15 credit hours
Summer 2009. The Ohio State University College of Medicine, NEURSGY 999 Dissertation Research NEURSGY 999. 5 credit hours
Summer 2009. The Ohio State University, BMS Honors Research Ex[perience BMS 720.1. 5 credit hours
Autumn 2009. The Ohio State University College of Medicine, IBGP 999 Dissertation Research IBGP 999. 15 credit hours
Autumn 2009. The Ohio State University, NEURSGY 999 Dissertation Research NEURSGY 999. 5 credit hours
Autumn 2009. The Ohio State University College of Medicine, BMS Honors Research Experience BMS 720.1. 5 credit hours
Autumn 2009. The Ohio State University, NGSY 825 Tumor Microenvirnment NGSY 825. 5 credit hours
Winter 2010. The Ohio State University College of Medicine, IBGP 999 DISSERTATION RESEARCH IBGP 999.
Winter 2010. The Ohio State University College of Medicine, BMS 720.1 BMS Honors Research Experience BMS 720.1. 5 credit hours
Winter 2010. The Ohio State University College of Medicine, NEURSGY 999 Dissertation Research NEURSGY 999. 5 credit hours
Winter 2010. The Ohio State University College of Medicine, IBGP 702.4 Cancer Biology Module IBGP 702.4. 10 credit hours.
Spring 2010. The Ohio State University College of Medicine, IBGP 703.05 BIOL HUMN DISEASE IBGP 703.05. 5 credit hours.
Spring 2010. The Ohio State University College of Medicine, Integrated Biomedical Science. 793 Individual Studies 793. 15 credit hours
Spring 2010. The Ohio State University College of Medicine, Integrated Biomedical Science. IBGP Dissertation Res IBGP 999. 18 credit hours
Spring 2010. The Ohio State University College of Medicine, Integrated Biomedical Science. NEURSGY Dissertation Res NEURSGY 999. 18 credit hours
Summer 2010. The Ohio State University College of Medicine, Integrated Biomedical Science. IBGP 793 Individual Studies IBGP 793. 15 credit hours
Summer 2010. The Ohio State University College of Medicine, Integrated Biomedical Science. IBGP 999 Dissertation Res IBGP 999. 18 credit hours
Summer 2010. The Ohio State University College of Medicine, Integrated Biomedical Science. NEURSGY 999 Dissertation Res NEURSGY 999. 18 credit hours
Summer 2010. The Ohio State University College of Medicine, BMS 720.1 BMS Honors Research Experience BMS 720.1. 5 credit hours
Autumn 2010. The Ohio State University College of Medicine, Integrated Biomedical Science. IBGP 793Individual Studies IBGP 793. 15 credit hours
Autumn 2010. The Ohio State University College of Medicine, Integrated Biomedical Science. IBGP 999 Dissertation Res IBGP 999. 18 credit hours
Autumn 2010. The Ohio State University College of Medicine, Neurological Surgery. NEURSGY 999 DISSERTATION Research NEURSGY 999. 18 credit hours
Autumn 2010. The Ohio State University College of Medicine, neurosurgery. NGSY 825 Tumor Microenvirnment NGSY 825. 2 credit hours.
Winter 2011. The Ohio State University College of Medicine, The College of Medicine. IBGP 999 DISSERTATION Research IBGP 999. 18 credit hours
Winter 2011. The Ohio State University, Graduate School. ngsp797 Seminar In Neurosc NGSP 797. 1 credit hours.
Winter 2011. The Ohio State University College of Medicine, Integrated Biomedical Science. NEURSGY 999 Dissertation Res NEURSGY 999. 18 credit hours
Spring 2011. The Ohio State University College of Medicine, The College of Medicine. IBGP 999 Dissertation Res IBGP 999. 18 credit hours
Spring 2011. The Ohio State University College of Medicine, The College of Medicine. IBGP 702.04 Cancer Biology IBGP 702.04. 2 credit hours.
Spring 2011. The Ohio State University College of Medicine, The College of Medicine. IBGP 793 Individual Studies IBGP 793. 15 credit hours
Spring 2011. The Ohio State University College of Medicine, The College of Medicine. IBGP 703.05 Biol Humn Dis 3 703.05. 10 credit hours
Spring 2011. The Ohio State University College of Medicine, Neurological Surgery. Research 999. 18 credit hours
Summer 2011. The Ohio State University College of Medicine, Integrated Biomedical Science Graduate Program. IBGP 999 DISSERTATION RESEARCH 999. 1 credit hours
Summer 2011. The Ohio State University College of Medicine, Neurological Surgery. NEURSGY 999 Dissertation research Neursgy 999. 18 credit hours
Summer 2011. The College of Medicine COLMBUS, Neurological Surgery. Research 999 . 18 credit hours
Summer 2011. The College of Medicine COLMBUS, Integrated Biomedical Science. Dissertation Res 999 . 18 credit hours
Autumn 2011. The Ohio State University, Biomedical Science Survey BMS 100. 1 credit hours
Autumn 2011. The Ohio State University, Neurological Surgery. NGSY 825 Tumor Microenvironment NGSY 825. 2 credit hours.
Autumn 2011. The Ohio State University College of Medicine, IBGP706 IBGP 706.
Autumn 2011. The College of Medicine COLMBUS, Integrated Biomedical Science. Dissertation Res 999 . 18 credit hours
Autumn 2011. The College of Medicine COLMBUS, Neurological Surgery. Research 999 . 18 credit hours
Autumn 2011. The College of Medicine COLMBUS, Integrated Biomedical Science. Individual Studies 793 . 15 credit hours
Autumn 2011. The College of Medicine COLMBUS, Neurological Surgery. Tumor Microenv 825 . 2 credit hours
Winter 2012. The College of Medicine COLMBUS, Integrated Biomedical Science. Dissertation Res 999 . 18 credit hours
Winter 2012. The College of Medicine COLMBUS, Neurological Surgery. Research 999 . 18 credit hours